We serve Chemical Name:5-Fluorobenzo[d]thiazol-2(3H)-one CAS:1065678-31-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-Fluorobenzo[d]thiazol-2(3H)-one](https://a.dearchem.com/CAS2/1065678-31-0.png)
Chemical Name:5-Fluorobenzo[d]thiazol-2(3H)-one
CAS.NO:1065678-31-0
Synonyms:5-fluoro-3H-1,3-benzothiazol-2-one
Molecular Formula:C7H4FNOS
Molecular Weight:169.17600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:61.10000
Exact Mass:169.00000
LogP:1.72870
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-fluoro-3H-1,3-benzothiazol-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-fluoro-3H-1,3-benzothiazol-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-fluoro-3H-1,3-benzothiazol-2-one Use and application,5-fluoro-3H-1,3-benzothiazol-2-one technical grade,usp/ep/jp grade.
Related News: Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. 5-Fluorobenzo[d]thiazol-2(3H)-one manufacturer Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California. 5-Fluorobenzo[d]thiazol-2(3H)-one supplier Beta Bionics is pursuing regulatory approval of its insulin-only bionic pancreas, followed by its dual-hormone system, which will also administer a glucagon analog in order to raise blood-sugar levels without the need to consume carbohydrates. Beta Bionics operates in Massachusetts and California. 5-Fluorobenzo[d]thiazol-2(3H)-one vendor The company’s pharmaceutical intermediate business is expected to maintain a growth rate of more than 30%. 5-Fluorobenzo[d]thiazol-2(3H)-one factory China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%.
